NOVEL BISPYRAZOLE SYNTHESIS
1355
4,4’-[(4-Nitrophenyl)methylene]bis(3-methyl-1-phenyl-1H-pyrazol-5-ol)
(Table 3, Entry 3) (3c). IR (KBr): 3422, 3056, 2972, 2920, 1604, 1580, 1504, 1348,
1
1108, 756, 740 cmꢁ1. H NMR (300 MHz, CDCl3): 2.35 (s, 6 H), 5.46 (s, 1 H),
7.20–7.40 (m, 4H), 7.38 (d, 2H). 7.73–7.78 (dd, 2H), 8.38–8.42 (dd, 2H), 13.52 (bs,
2H) d (ppm). 13C NMR (75 MHz, CDCl3): 14.2, 30.9, 100.9, 121.6, 122.1, 128.0,
129.6, 130.1, 140.3, 146.2, 146.4, 148.8, 150.3 d (ppm). Mp: 224–226 ꢀC.
4,4’-[(2-Nitrophenyl)methylene]bis(3-methyl-1-phenyl-1H-pyrazol-5-ol)
(Table 3, Entry 4) (3d). IR (KBr): 3450, 3070, 2910, 1610, 1555, 1495, 1360, 1300,
.
835, 740, 690 cmꢁ1 1H NMR (300 MHz, CDCl3): 2.29 (s, 6H), 5.19 (s, 1H),
7.35–7.40 (m, 4H), 7.45 (d, 1H), 7.48 (t, 4H), 7.73 (d, 4H), 7.83 (d, 1H), 13.52 (bs,
2H) d (ppm). 13C NMR (75 MHz, CDCl3): 14.2, 30.4, 101.3, 121.6, 122.1, 128.0,
129.6, 129.7, 130.1, 130.4, 135.2, 140.2, 146.0, 146.4, 148.9 d (ppm). Mp: 224–226 ꢀC.
4,4’-[(3-Chlorophenyl)methylene]bis(3-methyl-1-phenyl-1H-pyrazol-
5-ol) (Table 3, Entry 5) (3e). IR (KBr): 3420, 3110, 2980, 1605, 1470, 1415, 1356,
1
1290, 1110, 1065, 875, 750 cmꢁ1. H NMR (300 MHz, CDCl3): 2.33 (s, 6H), 4.99 (s,
1H), 7.10–7.22 (m, 6H), 7.38–7.42 (d, 6H), 7.48–7.51 (m, 2H), 13.80 (bs, 2H) d
(ppm). 13C NMR (75 MHz, CDCl3): 14.5, 32.4, 100.3, 121.8, 125.6, 126.9, 128.0,
128.2, 129.6, 129.8, 132.4, 140.4, 144.3, 146.2, 146.5 d (ppm). Mp: 152–154 ꢀC.
4,4’-[(2-Hydroxyphenyl)methylene]bis(3-methyl-1-phenyl-1H-pyrazol-
5-ol) (Table 3, Entry 6) (3f). IR (KBr): 3455, 3075, 2920, 1616, 1550, 1498, 1388,
1
1356, 1305, 838, 746, 695 cmꢁ1. H NMR (300 MHz, CDCl3): 2.15 (s, 6H), 5.05 (s,
1H), 7.20–7.28 (m, 4H), 7.35 (d, 1H), 7.40 (t, 4H), 7.66 (d, 4H), 7.78 (d, 1H), 9.21
(s, 1H), 13.80 (bs, 2H) d (ppm). 13C NMR (75 MHz, CDCl3): 14.2, 25.1, 101.6,
115.8, 118.3, 121.6, 126.2, 129.9, 127.8, 128.3, 129.7, 140.3, 146.3, 146.8, 155.1 d
(ppm). Mp: 218–220 ꢀC.
4,4’-[(4-Methoxylphenyl)methylene]bis(3-methyl-1-phenyl-1H-pyrazol-
5-ol) (Table 3, Entry 7) (3g). IR (KBr): 3436, 3088, 2921, 1584, 1514, 1434, 1137,
1029, 807, 658 cmꢁ1. 1H NMR (300 MHz, CDCl3): 2.38 (s, 6H), 3.42 (s, 3H), 5.09 (s,
1H), 7.11–7.16 (d, 4H), 7.34–7.37 (dd, 4H), 7.38–7.42 (m, 4H), 7.54–7.57 (dd, 2H),
13.89 (bs, 2H) d (ppm). 13C NMR (75 MHz, CDCl3): 14.1, 30.9, 55.1, 100.6,
110.6, 121.3, 127.8, 128.0, 129.5, 139.5, 140.1, 146.0, 146.6, 159.8 d (ppm). Mp:
176–178 ꢀC.
4,4’-[(Furan-2-yl)methylene]bis(3-methyl-1-phenyl-1H-pyrazol-5-ol)
(Table 3, Entry 8) (3h). IR (KBr): 3425, 2920, 1610, 1500, 1300, 1287, 764 cmꢁ1. 1H
NMR (300 MHz, CDCl3): 2.33 (s, 6H), 5.01 (s, 1H), 6.23 (dd, 1H), 6.55 (dd, 1H),
7.14–7.16 (d, 4H), 7.35–7.43 (m, 7H), 13.24 (bs, 2H) d (ppm). 13C NMR (75 MHz,
CDCl3): 13.6, 27.7, 98.7, 107.5, 121.5, 128.1, 128.3, 129.4, 140.2, 141.8, 144.3,
147.1, 155.2 d (ppm). Mp: 188–190 ꢀC.
4,4’-[(2-Propyl)methylene]bis(3-methyl-1-phenyl-1H-pyrazol-5-ol) (Table
3, Entry 9) (3i). IR: 3428, 3061, 2959, 2733, 1585, 1499, 1291, 1182, 1122, 1027,
1
901, 791, 750, 638 cmꢁ1. H NMR (300 MHz, CDCl3): 0.96 (d, 6H), 2.38 (s, 6H),
2.43 (m, 1H), 4.87 (s, 1H), 7.16–7.18 (d, 4H), 7.36 (m, 2H), 7.39–7.41 (m, 4H),
14.4 (bs, 2H) d (ppm). 13C NMR (75 MHz, CDCl3): 14.8, 21.9, 31.9, 40.4, 99.7,
121.7, 128.0, 129.6, 139.7, 145.3, 146.6 d (ppm). Mp: 212–214 ꢀC.